Name: Capital Market Publishers India Pvt. Ltd.
Telephone: 91-22-25229720

LOGIN HERE

Cancel

BSE Code : 541540 | NSE Symbol : SOLARA | ISIN : INE624Z01016 | Industry : Pharmaceuticals - Indian - Bulk Drugs & Formln |

Board Meeting

Announcement Date	Date Of Meeting	Purpose	Detail
26-Mar-2025	02-Apr-2025	Right Issue	Solara Active Pharma Sciences Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 02/04/2025 inter alia to consider and approve the First Call money Notice on the partly paid Equity Shares issued on Rights basis which is to be sent to the eligible Shareholders Solara Active Pharma Sciences Limited informed the exchange about the outcome of the Rights Issue Committee Meeting held today (i.e.) April 02, 2025 interalia to consider and approve the First call money notice to be sent to the eligible shareholders Outcome: Solara Active Pharma Sciences Limited informed the exchange about the Rights Issue Committee Meeting held today (i.e.) on April 02, 2025 interalia to consider and approve the First call money notice to be sent to the eligible shareholders (As per BSE Announcement Dated on 02/04/2025)
20-Mar-2025	26-Mar-2025	Right Issue	Solara Active Pharma Sciences Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 26/03/2025 inter alia to consider and approve the proposal of making First Call on 11998755 partly paid-up Equity Shares having a face value of Rs.10/- each (Rs.3.50/- paid-up) issued by the Company on rights basis in their Rights Issue Committee Meeting. Solara Active Pharma Sciences Limited had informed the Exchange that Rights Issue Commitee Meeting of the Board of Directors at its meeting held on March 26, 2025, has approved the making of first call of Rs. 3.50/- each (i.e.) 35% on the face value of Rs. 10/- each on the outstanding 1,19,98,755 partly paid up equity shares of the Company which were allotted on June 19, 2024 on a rights basis and fixation of Record date, tendering period and other matters Solara Active Pharma Sciences Limited has informed the Exchange that Board of Directors at its meeting held on March 26, 2025, has approved the making of first call of Rs. 3.50/- each (i.e.) 35% on the face value of Rs. 10/- each on the outstanding 1,19,98,755 partly paid-up equity shares of the Company which were allotted on June 19, 2024 on a right basis, fixation of Record date, Tendering period and other matters. Solara Active Pharma Sciences Limited has informed the exchange about the Record date for the purpose of making first call for the shares issued on Rights Basis. (As Per BSE Announcement Dated on 26.03.2025)
21-Feb-2025	21-Feb-2025	Subsidiary Company	Solara Active Pharma Sciences Limited has informed the Exchange regarding Appointment and Resignation of Chief Executive officer, Appointment and Resignation of Chief Financial Officer, Appointment of a Senior Managerial Personnel.
16-Jan-2025	24-Jan-2025	Quarterly Results	Solara Active Pharma Sciences Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 24/01/2025 inter alia to consider and approve Solara Active Pharma Sciences Ltd has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 24/01/2025 inter alia to consider and approve the Unaudited Standalone and Consolidated Financial Results for the quarter and nine months ended December 31 2024 and other matters. Solara Active Pharma Sciences Limited has informed the Exchange regarding Board meeting held on January 24, 2025 interalia to consider and approve the Unaudited Financial Results for the quarter ended December 31, 2024 and other matters. (As Per BSE Announcement Dated on: 24/01/2025)
14-Oct-2024	21-Oct-2024	Quarterly Results	Solara Active Pharma Sciences Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 21/10/2024 inter alia to consider and approve the Unaudited Standalone and Consolidated Financial Results for the quarter and half year ended September 30 2024 and other matters SOLARA : Solara Active Pharma Sciences Limited has informed the Exchange regarding Board meeting held on October 21, 2024 to consider and approve the Unaudited Standalone and Consolidated Financial Results for the quarter and half year ended September 30, 2024 and allotment of 49,000 Equity shares pursuant to exercise of ESOP Grant under SOLARA ESOP Plan ,2018. Read less.. Solara Active pharma Sciences Limited has informed the Exchange regarding Board meeting held on October 21, 2024 to consider and approve the Unaudited Standalone and Consolidated Financial Results for the quarter and half year ended September 30, 2024 and allotment of 49,000 equity shares pursuant to exercise of ESOP granted under SOLARA ESOP Plan 2018 Read less.. (As Per BSE Announcement Dated on 21.10.2024)
15-Jul-2024	22-Jul-2024	Quarterly Results	Solara Active Pharma Sciences Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 22/07/2024 inter alia to consider and approve unaudited financial results for the quarter ended June 30 2024. Unaudited financial results for the quarter ended June 30, 2024 (As per BSE Announcement Dated on 22/07/2024)
21-May-2024	29-May-2024	Accounts	Solara Active Pharma Sciences Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 29/05/2024 inter alia to consider and approve audited financial results (standalone and consolidated) of the Company for the quarter and year ended March 31 2024. Results for the period ended March 31, 2024 Outcome of Board Meeting (As Per BSE Announcement Dated on 29.05.2024)
05-Feb-2024	14-Feb-2024	Quarterly Results	Solara Active Pharma Sciences Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 14/02/2024 inter alia to consider and approve unaudited financial results for the period ended December 31 2023 Unaudited Financial Results for the period ended December 31, 2023 Resignation of Mr. P V Raghavendra Rao from the position of Chief Financial Officer of the Company from the close of business hours of February 15, 2024. Appointment of Mr. M Mohan as Executive Director of the Company with effect from February 14, 2024. (As Per BSE Announcement Dated on 14/02/2024)
07-Nov-2023	14-Nov-2023	Quarterly Results	Solara Active Pharma Sciences Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 14/11/2023 inter alia to consider and approve unaudited Financial Results for the period ended September 30 2023. Unaudited Financial Results for the quarter ended September 30, 2023 We hereby inform you that based on the recommendations of the Nomination & Remuneration Committee, the Board of Directors of the Company has appointed Mr. Rajendra Kumar Srivastava as Additional Non-Executive Independent Director and Mr. Rajiv Vijay Nabar as Additional Non- Executive Non-Independent Director of the Company with effect from November 14, 2023. (As per BSE Announcement Dated on 14/11/2023)
19-Oct-2023	19-Oct-2023	Change in Other Executives	In accordance with SEBI (LODR), Regulations, 2015, it is hereby informed that the Board in its meeting held today has approved the appointment of Mr. P.V Raghavendra Rao as Chief Financial Officer of the Company and designated him as KMP with effect from October 26, 2023.
04-Aug-2023	14-Aug-2023	Quarterly Results	Solara Active Pharma Sciences Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 11/08/2023 inter alia to consider and approve the un-audited financial results (standalone and consolidated) of the Company for the quarter ended June 30 2023 amongst other matters. The Board Meeting to be held on 11/08/2023 has been revised to 14/08/2023 The Board Meeting to be held on 11/08/2023 has been revised to 14/08/2023 (As per BSE Announcement Dated on 07/08/2023) Pursuant to Regulation 30 of SEBI (LODR), this is to inform you that Board of Directors at their meeting held today (August 14, 2023) have approved and reconstituted the composition of Audit Committee, Risk Mangement Committee and Corporate Social Responsibility Committee. (As Per BSE Announcement Dated on 14.08.2023)
30-Jun-2023	05-Jul-2023	Right Issue	Solara Active Pharma Sciences Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 05/07/2023 inter alia to consider and approve Pursuant to Regulation 29 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations 2015 ('Listing Regulations) this is to inform you that a meeting of the Board of Directors of the Company is scheduled to be held on Wednesday July 5 2023 inter alia to consider the proposal to issue equity shares to existing shareholders on Rights basis as may be permitted under applicable law subject to such regulatory/statutory approvals as may be required. SOLARA ACTIVE PHARMA SCIENCES LIMITED has informed BSE about Board Meeting to be held on 05 Jul 2023 to consider Fund raising. (As Per BSE Announcement Dated on 30.06.2023) 1. The offer and issuance of equity shares of face value of ?10 each of the Company (the 'Equity Shares') for an aggregate amount, including premium, not exceeding Rs. 450 Crores (Rupees Four Hundred and Fifty Crores) by way of a rights issue to the eligible equity shareholders of the Company as on the record date (to be determined and notified subsequently), in accordance with applicable laws, including the Securities and Exchange Board of India (Issue of Capital and Disclosure Requirements) Regulations, 2018, as amended, subject to such approvals, as may be required under the applicable laws ('Rights Issue'). Pursuant to Regulation 30 of SEBI (LODR), 2015 WE wish to inform that the Board of Directors has considered and approved for issuance of equity shares to existing shareholders on Rights Basis (As Per BSE Announcement dated on 05.07.2023)
04-May-2023	12-May-2023	Accounts	Solara Active Pharma Sciences Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 12/05/2023 inter alia to consider and approve the audited financial results (standalone and consolidated) of the Company for the quarter and year ended March 31 2023 amongst other matters. Audited financial results (standalone and consolidated) of the Company for the quarter and Year ended March 31, 2023, pursuant to Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2015. A copy of the audited financial results (standalone and consolidated) for the quarter and year ended March 31, 2023, along with the Auditors report for the said period and press release on the same is attached. Pursuant to Regulation 30 read with Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015, ('Listing Regulations'), we wish to inform that based on the recommendation of the Audit Committee, the Board of Directors of the Company at its meeting held today, i.e. May 12, 2023, has, subject to the approval of the members of the Company to be obtained in the ensuing Annual general meeting of the Company, recommended the re-appointment of Deloitte Haskins & Sells LLP, Chartered Accountants (Firm Registration Number: 117366W/W-100018) as the Statutory Auditors of the Company under Section 139 of the Companies Act 2013. (As Per BSE Announcement Dated on 12/05/2023)
19-Jan-2023	25-Jan-2023	Quarterly Results	Solara Active Pharma Sciences Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 25/01/2023 inter alia to consider and approve the unaudited financial results (standalone and consolidated) of the Company for the quarter and nine months ended December 31 2022 amongst other matters. Unaudited financial results (standalone and consolidated) of the Company for the quarter ended December 31, 2022. A copy of the unaudited financial results (standalone and consolidated) for the quarter ended December 31, 2022, along with the Limited Review Report by the Auditors and press release is attached. Outcome of Board Meeting held on January 25, 2023 Pursuant to Regulation 30 read with Part A, Schedule Ill of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ('LODR Regulations'), we wish to inform you that the Board of Directors of the Company has appointed Mr. Poorvank Purohit as Chief Executive Officer and as Key Managerial Personnel (KMP) with effect from February 3, 2023. (As per BSE Announcement Dated on 25/01/2023)
02-Nov-2022	09-Nov-2022	Quarterly Results	Solara Active Pharma Sciences Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 09/11/2022 inter alia to consider and approve the unaudited financial results (standalone and consolidated) of the Company for the quarter and half year ended September 30 2022 amongst other matters. We wish to inform that meeting of Board of Directors of the company held today (i.e., November 9, 2022), the Directors has inter-alia approved Unaudited financial results (standalone and consolidated) of the Company for the quarter and half year ended September 30, 2022, pursuant to Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2015. A copy of the unaudited financial results (standalone and consolidated) along with the Limited Review Report by the Auditors and press release is attached. (As Per BSE Announcement Dated on 09/11/2022)

1 2 3

LOGIN HERE

Solara Active Pharma Sciences Ltd

Board Meeting